Join us for the 2019 Healthcare Entrepreneurship & Innovation Exchange hosted by the UNC Kenan-Flagler Business School Healthcare Club and the Center for the Business of Health.
Please join Center for the Business of Health alumni board members and Markus Saba, Executive Director for the UNC Center for the Business of Health, to discuss the current state of Healthcare in the United States.
Access challenges associated with high-cost pharmaceuticals have jump started discussion of solutions ranging from state-based boards reviewing drug price increases to harnessing Medicare’s purchasing power for “price negotiation” to old-fashioned price-setting.
Save the date for the annual Business of Healthcare Conference. This conference brings together students, executives from the private sector, academic researchers and public policy leaders to discuss the most pressing problems in healthcare today.
 

Related Publications

New Drugs, New Ideas: Payment Policy Innovations for High-Cost Pharmaceuticals

October 01, 2019

Access challenges associated with high-cost pharmaceuticals have jump started discussion of solutions ranging from state-based boards reviewing drug price increases to harnessing Medicare’s purchasing power for “price negotiation” to old-fashioned price-setting. More

How FDA Can Act On E-Cigarettes And Protect The Public Health

September 19, 2019

After years of decline, increases in American youth tobacco usage have pushed the tobacco control debate back into the forefront of the public health conversation. Youth tobacco use increased from 2011 to 2018, largely driven by e-cigarette usage, which grew from 1.5% to 20.8% of American high school students, representing an increase of 2.83 million adolescents. Despite extensive evidence that e-cigarette chemicals cause morbidity including immediate, harmful changes in endothelial function in healthy nonsmokers, 72% of teenage e-cigarettes users believe e-cigarettes cause some, little, or no harm. More

FTC Concerns Over Bristol-Myers Deal Raise Questions

August 05, 2019

On Jan. 3, 2019, Bristol-Myers Squibb Co. announced its proposed acquisition of Celgene Corp. for approximately $74 billion. The Federal Trade Commission issued requests for additional information and documentary materials to the companies on March 25, 2019, that were “focused on marketed and pipeline products for the treatment of psoriasis.” In order to address the FTC’s concerns, BMS plans to divest Celgene’s Otezla (apremilast) drug, which is a phosphodiesterase-4 inhibitor indicated for the treatment of moderate to severe psoriasis and psoriatic arthritis. Psoriasis is an autoimmune disease with multiple subtypes, with large skin plaques being the most common manifestation.   More

Redefining the Physician’s Role in Cost-Conscious Care: The Potential Role of the Electronic Health Record

July 12, 2019

Recent health policy efforts have attempted to promote constructive conversations regarding cost-effectiveness by increasing transparency for both patients and physicians. Spurred by access and cost challenges resulting from increasing pharmaceutical prices, the Centers for Medicare & Medicaid Services (CMS) proposed a rule that would require direct-to-consumer prescription drug advertisements to include the list price for a typical 30-day course of therapy, according to their weighted average cost. This Viewpoint discusses implementing price transparency for health care products and services where physicians spend an increasing proportion of their time—in electronic health records (EHRs). More